1974
DOI: 10.3109/02841867409129875
|View full text |Cite
|
Sign up to set email alerts
|

Blood Lymphocytes after Radiation Therapy of Mammary Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

1975
1975
1991
1991

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 67 publications
(17 citation statements)
references
References 42 publications
0
17
0
Order By: Relevance
“…Recently, it was found that local radiotherapy of women with carcinoma of the breast or patients with carcinoma of the urinary bladder or prostate causes a significant reduction of the lymphocytes' response to PPD (5,8). The radiotherapy was observed to deplete the peripheral blood lympliocyte population by approximately 509^ (4,5,8). The percentage of lymphocytes that nonspecifitally adhere sheep erythrocytes in vitro (mainly T cells) increased after irradiation, whereas lymphocytes with membrane-associated receptors for activated C} were decreased (mainly B cells) {4, 5).…”
mentioning
confidence: 99%
“…Recently, it was found that local radiotherapy of women with carcinoma of the breast or patients with carcinoma of the urinary bladder or prostate causes a significant reduction of the lymphocytes' response to PPD (5,8). The radiotherapy was observed to deplete the peripheral blood lympliocyte population by approximately 509^ (4,5,8). The percentage of lymphocytes that nonspecifitally adhere sheep erythrocytes in vitro (mainly T cells) increased after irradiation, whereas lymphocytes with membrane-associated receptors for activated C} were decreased (mainly B cells) {4, 5).…”
mentioning
confidence: 99%
“…However, at the completion of treatment, the mean total lymphocyte count of 503/mm3 was 4 SD below the mean for normal controls. Acute lymphocytopenia after a course of radiation has been described in a variety of clinical situations involving localized or extended field radiotherapy (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Recovery usually begins shortly after completion of treatment (6,7,12), and continues through the next 1-2 yr.…”
Section: Introductionmentioning
confidence: 99%
“…Mo¬ nocytes were identified with the aid of Leu M 3 monoclo¬ nal antibodies (Becton Dickinson Co) followed by incu¬ bation with FITC-conjugated F(ab')2 fragments of rabbit anti-mouse IgG (Sigma Chemical Co, St. Louis, MO). Lymphocytes expressing membrane receptors for acti¬ vated C'3 were identified as cells forming rosettes with heterologous erythrocytes treated with specific IgM an¬ tibodies which have been incubated with fresh serum as a source of complement as described (16). These cells will be termed EAC-rosette-forming.…”
Section: Identification Of Lymphocyte Subsetsmentioning
confidence: 99%